Schedule 13G ownership disclosure

TRAVERE THERAPEUTICS INC

Common Stock · CUSIP: 89422G107

Event date: 2025-03-31

Filing-level shares
5,014,020
Percent of class
5.65%
  • The Vanguard Group

    Shares: 5,014,020 · Class: 5.65%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000932471-25-000623
Form type
SCHEDULE 13G/A
Filer
Travere Therapeutics, Inc.
CIK
CIK 1438533
Filed
Apr 30, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub